ADAR1 Capital Management LLC Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

ADAR1 Capital Management LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 56.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,361 shares of the biopharmaceutical company’s stock after purchasing an additional 490 shares during the quarter. ADAR1 Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $969,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the stock. Integrated Wealth Concepts LLC raised its position in Regeneron Pharmaceuticals by 40.1% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 748 shares of the biopharmaceutical company’s stock valued at $786,000 after purchasing an additional 214 shares in the last quarter. IHT Wealth Management LLC increased its position in Regeneron Pharmaceuticals by 17.2% during the 3rd quarter. IHT Wealth Management LLC now owns 701 shares of the biopharmaceutical company’s stock worth $736,000 after purchasing an additional 103 shares during the period. Kovitz Investment Group Partners LLC boosted its holdings in Regeneron Pharmaceuticals by 54.6% during the third quarter. Kovitz Investment Group Partners LLC now owns 3,691 shares of the biopharmaceutical company’s stock worth $3,880,000 after buying an additional 1,303 shares in the last quarter. EP Wealth Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 16.6% in the third quarter. EP Wealth Advisors LLC now owns 1,467 shares of the biopharmaceutical company’s stock valued at $1,542,000 after buying an additional 209 shares in the last quarter. Finally, National Bank of Canada FI lifted its stake in Regeneron Pharmaceuticals by 66.3% in the 3rd quarter. National Bank of Canada FI now owns 71,159 shares of the biopharmaceutical company’s stock valued at $74,805,000 after buying an additional 28,365 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $573.45 on Monday. The stock has a 50 day moving average price of $676.70 and a 200 day moving average price of $776.59. The company has a market capitalization of $62.69 billion, a price-to-earnings ratio of 14.98, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52-week low of $536.30 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the prior year, the company earned $11.86 EPS. Regeneron Pharmaceuticals’s revenue was up 10.3% on a year-over-year basis. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.61%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 2.30%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on REGN shares. TD Cowen cut their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research report on Tuesday, February 4th. Piper Sandler cut their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. BMO Capital Markets dropped their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 4th. Sanford C. Bernstein cut their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Finally, Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $966.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.